1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical and genetic characteristics of our study population and prognostic value by univariate Cox regression test
Mean (SD) or No. (%) Hazard Ratio (95% CI) P Value
Age (years) 55.5 (13.4) 1.02 (0.990–1.06) .172
Sex
 Men 21 (63.6%) 0.887 (0.393–2.00) .772
 Women 12 (36.4%) 
Radiation dose
 Hypofractionated (45 Gy in 15 fractions) 6 (18.2%) 1.51 (0.593–3.84) .388
 Conventional long course (>60 Gy) 27 (81.8%) 
Karnofsky Performance Status score
 <70 3 (9.1%) 0.820 (0.193–3.50) .789
 ≥70 30 (90.9%) 
IDH1 or 2 mutation
 Present 2 (6.1%) 0.324 (0.0432–2.436) .274
 Absent 31 (93.9%) 
MGMT promoter methylation
 Methylated 22 (66.7%) 0.256 (0.113–0.577) .001
 Unmethylated 11 (33.3%) 
Baseline T2 high-signal-intensity volume (mL) 59.5 (29.0) 0.996 (0.982–1.01) .573
Posttreatment T2 high-signal-intensity volume (mL) 16.6 (24.8) 0.996 (0.978–1.01) .668
Percentage change T2 high-signal-intensity volume −64.3% (44.8%) 1.04 (0.412–2.63) .934